GlassScriptPhysician profile
Krishna Patel
NPI 1154868008
$567.56
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $410 · 2022: $157.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $129.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $79.23 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $64.76 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $63.36 | 2021 | |
| Lilly USA, LLC | $60.94 | 2021 | |
| Esperion Therapeutics, INC. | $35.55 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.13 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.20 | 2021 | |
| Abbott Laboratories | $24.11 | 2022 | |
| Amarin Pharma, INC. | $21.35 | 2021 | |
| Pfizer INC. | $12.84 | 2021 | |
| Astellas Pharma US INC | $12.79 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.